Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201806-09 A phase 1 study of OLX10010, a potential treatment for hypertrophic scar, using a self-delivering RNAi compound for global market entrance, and its IND approval for phase 2 study(Others, Chemical) [2019-02-22]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

IND approval of phase 2 clinical trial with OLX10010, a candidate molecule of the treatment for hypertrophic scar, after phase 1 clinical trial in UK for the penetration into the global market

- Completion of phase 1 clinical trial with OLX10010 in UK

- IND approval of phase 2 clinical trial from regulatory authority either USA or Europe

Unmet Medical Need & Target Patients

Target patient population are the adults with hypertrophic scar, mainly developed from trauma and surgeries which have more demand on the plastic and reconstructive surgeries such as cesarean section, breast augmentation, liposuction, and so on.

 

There is no systemic and accurate epidemiology data on hypertrophic scar, however, number of target patients is assumed approximately 32 million worldwide according to the stat on the surgeries and related data. No approved prescription medicine yet in the market.

Status

Ongoing phase 1 clinical trial in UK, and planned to complete it in 2019.

Intellectual Property

Patents related to the structure of siRNA: asymmetric siRNA (PCT/KR2008/007530)

Patents for self-delivery of siRNA into the cell and development candidate molecule for OLX101 program: cp-asiRNA (PCT/KR2013/004463)

Competitive Advantages

A few developers are under development of hypertrophic scar treatments in the early clinical stage. OLX10010 showed the potency approximately 7.4 times as high as the leading molecule in the clinical stage, which may benefit in terms of therapeutic dosage and cost competitiveness.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code